This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
21 Dec 2011

ChemDiv Inks Discovery Pact with J&J Units

ChemDiv has signed a multi-project research and collaboration agreement with Janssen Pharmaceutica and Tibotec Pharmaceuticals.

Global chemistry-driven contract research organization ChemDiv, Inc. has signed a multi-project research and collaboration agreement with Janssen Pharmaceutica and Tibotec Pharmaceuticals, two Johnson & Johnson subsidiaries.

 

ChemDiv will apply its integrated drug discovery expertise and technologies to identify novel small molecules against targets to be jointly agreed upon. For each research project, Janssen or Tibotec will fund certain R&D costs of ChemDiv. ChemDiv will be eligible for certain success milestones.

 

ChemDiv will conduct much of the research under this arrangement through its Moscow subsidiary, ChemDiv Research Institute (CDRI), anchored at the ChemRar High Tech Centre. The research will also be supported by ChemDiv

Related News